Dr Seth Cheetham's research program focuses on next generation RNA vaccines and therapeutics. mRNA technologies are a new paradigm for therapy and vaccinology; however, their full potential is yet to be realised. First-generation mRNA vaccines have simple designs that do not yet take advantage of the latest advances in RNA sciences. They use approaches including modified nucleotides, RNA structural elements, high-throughput screening, circularisation, and transcriptomics to improve the properties of therapeutic RNAs. These technologies will enable next generation vaccines with improved immunogenicity, tolerability, cell-type-specificity and stability. Their team are analysing the impact of these new mRNA technologies on delivery efficiency and innate immune activation. The mRNAs that the Cheetham Lab designs are used in diverse applications including vaccines, protein-replacement therapies, and onco-immunology to treat intractable diseases.